Navigation Links
Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce First Patient Dosed in Phase II Study of VPD-737 in Prurigo Nodularis
Date:8/4/2014

SOUTH SAN FRANCISCO, Calif., Aug. 4, 2014 /PRNewswire/ -- Velocity Pharmaceutical Development, LLC ("VPD") and Tigercat Pharma, Inc., ("Tigercat") today announced that the first patient has been dosed in a double-blind, placebo-controlled Phase II study to evaluate the efficacy and safety of VPD-737 (serlopitant), administered orally in patients with prurigo nodularis.  Separately, VPD is also conducting a Phase II clinical trial in the United States evaluating VPD-737 in patients with chronic pruritus.

Dr. Edward Schnipper, Tigercat's Chief Medical Officer, stated "We are delighted to announce that the first patient has been dosed in this important Phase II study.  Prurigo nodularis is a debilitating disease and the current standard of care does not effectively address this condition.  We believe VPD-737 is a promising pharmacological option and we are eager to see results from this study, which along with data from our chronic pruritus study, will be available in 2015."

The trial is a double-blind, placebo-controlled Phase II study in sixty patients with prurigo nodularis, an orphan disease.  The study is designed to determine the safety, tolerability, and efficacy of VPD-737, an NK-1 receptor antagonist, and is underway at four sites in Germany.  Patients in the study will receive either 5 mg of VPD-737 or placebo, taken once daily, for a period of eight weeks.

VPD-737 was exclusively licensed by Merck to VPD in 2012.

About Tigercat Pharma, Inc.
Tigercat Pharma, Inc., is a largely "virtual" company which was created to hold the ownership of the VPD-737 development program.  Tigercat is funded by Velocity Pharmaceutical Holdings, LLC, and Remeditex Ventures, LLC.  The VPD-737 development program is managed under contract by VPD. 

About Velocity Pharmaceutical Development, LLC 
VPD is a pharmaceutical development organization dedicated to rapidly advancing promising drug candidates to clinical proof of concept using a highly virtual management model.  VPD seeks to acquire promising drug candidates, generally within a year of their entering human clinical trials or after initial human clinical data have been generated.  VPD then manages a development program for each drug candidate intended to generate convincing human proof of concept data (generally by conducting a phase 2 clinical trial).  Following successful human proof of concept, VPD then seeks a large pharmaceutical company acquirer for each program.  VPD is staffed by a seasoned team of clinical drug developers with expertise identifying attractive drug candidates, target markets, and designing and managing outsourced clinical trials.  This expert team manages multiple single asset companies to remove the costly overhead and misaligned incentives present in traditional biotechnology company structures.  VPD believes this new capital-efficient model will yield attractive new drugs to treat patients with significant unmet clinical needs.  The company is located in South San Francisco, California.  More information is available at www.vpd.net

About Velocity Pharmaceutical Holdings, LLC 
Velocity Pharmaceutical Holdings, LLC, is an entity funded by CMEA Capital that makes investments in highly virtual, project-focused pharmaceutical development companies that are managed by Velocity Pharmaceutical Development, LLC.  More information is available at www.vpd.net and www.cmea.com

About Remeditex Ventures, LLC 
Remeditex is a company that seeks to develop opportunities in need of commercial validation, guidance, and capital.  Its mission is to develop early stage biomedical science and make Texas and Colorado a preferred location for biotechnology companies, venture capitalists, and entrepreneurs by accelerating the pace of commercialization of biomedical research; help create and support a thriving biotechnology industry; attract biotech venture capital to Texas and Colorado; and achieve significant returns to support the next generation of promising science. More information is available at www.remeditex.com.

Contact:
Leslie Loven
1-415-524-7326
leslie@vpd.net


'/>"/>
SOURCE Velocity Pharmaceutical Development, LLC
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Velocity Pharmaceutical Development Announces Appointment of Stuart Sedlack as Senior Vice President, Business Development
2. Velocity Pharmaceutical Development and Remeditex Ventures Announce Collaboration Agreement and Initial Co-Investment
3. Pharmaceuticals Learning the Language of the New Healthcare Landscape
4. Valeant Pharmaceuticals And Pershing Square Respond To Frivolous Allergan Lawsuit
5. Isis Pharmaceuticals Initiates Phase 3 Study of ISIS-SMN Rx in Infants with Spinal Muscular Atrophy
6. Inovio Pharmaceuticals to Host Second Quarter 2014 Financial Results Call on August 11, 2014
7. Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results
8. Auxilium Pharmaceuticals, Inc. To Announce Second Quarter 2014 Results On August 7, 2014
9. Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs
10. The Galien Foundation Announces 2014 Prix Galien USA Nominees for "Best Biotechnology Product," "Best Pharmaceutical Agent," and "Best Medical Technology"
11. Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... March 24, 2017 ShangPharma, a ... and cost-effective drug development and discovery services, ... biotechnology industry, announced today the intent for ... will be consolidating the Contract Research Organizations ... Shanghai ChemPartner. These entities include ChemPartner Shanghai, ...
(Date:3/24/2017)... India , March 24, 2017 A ... market has been growing rapidly as the global sales of Adcetris ... the growth in the antibody drug conjugates market is driven by ... of cancer and wider therapeutic window offered by ADCs. ... Browse 3 Tables and 94 ...
(Date:3/24/2017)... , March 24, 2017  Eli Lilly and ... plans to invest $850 million in its U.S. ... across its U.S. enterprise, including research laboratories, manufacturing ... are being driven by demand for Lilly products, ... medicines in development targeting cancer, pain, diabetes and ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... , ... “Vintage and Harvest A Cultivation of Christian Love” is the creation ... North Carolina with his wife, Anna Marie. He and his wife are the proud ... also the author of “Shadow and Substance.” , “Love, the agape kind, is seen ...
(Date:3/23/2017)... ... 2017 , ... In 2016 the World Health Organization declared the Zika virus ... Zika-related cases in the Americas within the next year. Lyme disease is one of ... skyrocketing to an estimated 329,000. Yet, Zika, Lyme and other insect borne illnesses are ...
(Date:3/23/2017)... ... March 23, 2017 , ... Demonstrating ... communities, 16 more public health departments have been awarded national accreditation through the ... million people into the expanding network of communities across the nation whose health ...
(Date:3/23/2017)... ... March 23, 2017 , ... The IoT (Internet of Things) is ... making a huge impact on businesses and individual consumers alike. Laboratories can maximize ... have a value anywhere from $4 trillion to $11 trillion dollars by the year ...
(Date:3/23/2017)... , ... March 23, 2017 ... ... financial services firm serving the families and businesses of the Norwalk and ... program. Northern Ohio Recovery Center (N.O.R.A.) is a nonprofit, community-based substance abuse ...
Breaking Medicine News(10 mins):